| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price |
|---|---|---|---|---|---|---|---|---|
| ALPL | Cynomolgus ALPL Protein, His Tag (active enzyme, MALS verified) | Cynomolgus | HEK293 | ![]() | MALSSDS-PAGE | $380.00 100ug | ||
| ALPL | Human ALPL Protein, His Tag, low endotoxin (active enzyme, MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $390.00 100ug | ||
| ALPL | HRP-Human ALPL Protein, His Tag | Human | HEK293 | ![]() | SDS-PAGE | $305.00 25ug | ||
| ALPL | Mouse ALPL Protein, His Tag (active enzyme, MALS verified) | Mouse | HEK293 | ![]() | MALSSDS-PAGE | $380.00 100ug |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| ALXN-1850 | ALXN-1850 | Phase 3 Clinical | Alexion Pharmaceuticals Inc | Hypophosphatasia | Details |
| DS-1211 | DS-1211 | Phase 2 Clinical | Daiichi Sankyo Co Ltd, Sanford Burnham Prebys Medical Discovery Institute | Ossification, Heterotopic; Pseudoxanthoma Elasticum | Details |
| ALXN-1910 | ALXN-1910 | Phase 1 Clinical | Alexion Pharmaceuticals Inc | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Asfotase alfa | sTNALP-FcD10; ALXN-1215; sALP-FcD10; ENB-0040 | Approved | Alexion Pharmaceuticals Inc | Strensiq | Japan | Hypophosphatasia | Alexion Pharmaceuticals Inc | 2015-07-03 | Hypophosphatasia | Details |